Enliven Therapeutics Stock
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Sign up today and learn more about Enliven Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Enliven Therapeutics Stock
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives. The company's discovery process combines clinically validated biological targets and industry-leading chemistry to address the limitations of existing therapies. This approach allows us to efficiently and effectively develop precision oncology therapeutics that enhance overall patient well-being. Founded in July 2019 by Sam Kintz, MBA, Joe Lyssikatos, PhD, and Anish Patel, PharmD, Enliven Therapeutics is based in Boulder, Colorado.
Funding History
| December 2020 | $55.0M |
|---|---|
| January 2022 | $85.0M |
Management
Co-Founder and CEO
Sam Kintz
Co-founder and Chief Operating Officer
Anish Patel
Co-founder and Chief Scientific Officer
Joe Lyssikatos
Board Member
Rich Heyman
Board Member
Mika Derynck
Board Member
Andrew Phillips
Board Member
Jake Bauer
Press
seekingalpha - Mar, 19 2024
Enliven Therapeutics announces $90M private placement to fund R&D activitiesbizwest - Mar, 16 2024
Expenses grow as Enliven Therapeutics drug trials ramp upseekingalpha - Nov, 10 2023
Enliven Therapeutics GAAP EPS of -$0.51seekingalpha - Sep, 29 2023
Enliven Therapeutics 10% owner disposes of ~$3M worth of sharesbioworld - Sep, 7 2023
Enliven Therapeutics divulges new HER2 inhibitors for cancerEquityZen Recognized As:
